BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. Nachrichten zur Aktie BioXcel Therapeutics Inc Registered Shs | A2JF20 | BTAI | US09075P1057 All of our products feature greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free. Zero analysts have provided estimates for BioXcel Therapeutics' earnings, with the lowest EPS estimate coming in at ($0.93) and The FDA authorized the IND application for the triple combination of BXCL701, bempegaldesleukin (produced by Nektar Therapeutics, Inc., or Nektar) and BAVENCIO® (avelumab, Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer. Market Data copyright © 2020 BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.We are focused on utilizing cutting-edge technology & innovative research to develop high value therapeutics aimed at transforming patients’ lives. BIOXCEL THERAPEUTICS AKTIE und aktueller Aktienkurs. BioXcel Therapeutics employs a unique AI platform an effort to reduce therapeutic development costs and potentially accelerate timelines, while aiming to increase the possibility of success. BioXcel Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The safety escalation portion of the trial is ongoing and will be followed by a two-stage efficacy portion. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics employs a unique AI platform an effort to reduce therapeutic development costs and potentially accelerate timelines, while aiming to increase the possibility of success. A data read-out is expected in 1H 2020. Wall Street brokerages forecast that BioXcel Therapeutics Inc (NASDAQ:BTAI) will announce earnings of ($0.76) per share for the current fiscal quarter, according to Zacks. We believe that this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.Targeting immuno-oncology and neuroscience disorders with significant unmet medical need and large market opportunityProprietary drug development approach aims to leverage existing approved drugs and/or clinically evaluated product candidatesDeveloping first-in-class drug candidates while aiming for a higher possibility of clinical and regulatory successPotential to provide clinical benefit to patients in need
BXCL501 … BioXcel Therapeutics, Inc. (BTI) is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.Our neuroscience and immuno-oncology programs utilize our approach to drug development.BXCL501 is an investigational sublingual thin film formulation of dexmedetomidine in development for acute treatment of agitation in multiple neuropsychiatric indications.BXCL701 is an investigational orally-available systemic innate immunity activator in development for the treatment of a rare form of prostate cancer and for the treatment of pancreatic cancer. About Us. AI-based Drug Development. We are focused on utilizing cutting-edge technology & innovative research to develop high value therapeutics aimed at transforming patients’ lives. Bio X Cell offers over 300 different InVivo grade antibodies. Our neuroscience and immuno-oncology programs utilize our approach to drug development. BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. Company’s Approach to Drug Development.